Table 7.
Association of MMP2 rs243866 (−1575 G/A) SNP with the age of disease onset and MoCA score.
| Phenotype | Patient Group | Genotypes | Best Model | p-Value | ||
|---|---|---|---|---|---|---|
| GG | GA | AA | ||||
| AOO | Whole | 77.97 ± 6.01 | 76.13 ± 5.72 | 76.43 ± 7.90 | Dominant | 0.024 * |
| APOE ε4 + | 76.57 ± 5.82 | 74.48 ± 5.07 | 76.45 ± 4.23 | Overdominant | 0.12 † | |
| APOE ε4 − | 79.11 ± 5.97 | 77.07 ± 5.91 | 76.40 ± 10.89 | Dominant | 0.073 † | |
| MoCA | Whole | 16.00 ± 6.17 | 14.41 ± 5.68 | 16.35 ± 5.38 | Overdominant | 0.073 ‡ |
| APOE ε4 + | 16.46 ± 5.92 | 14.59 ± 5.56 | 14.25 ± 4.43 | Dominant | 0.18 $ | |
| APOE ε4 − | 15.68 ± 6.36 | 14.31 ± 5.82 | 18.22 ± 5.70 | Overdominant | 0.14 $ | |
Age at onset (AOO) and Montreal Cognitive Assessment (MoCA) are presented as the mean and standard deviation. The “−” sign means the absence of the APOE ε4 allele, while the “+” sign denotes the presence of one or two of the APOE ε4 allele copies. Linear regression analysis was adjusted for * sex and APOE ε4 carrier status; † sex; ‡ age, sex, disease duration, and ApoE ε4 carrier status; $ age, sex, and disease duration. Significant p-values are shown in bold.